☆ 4.6 Article

Cost-Utility Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early HER-2 Positive Breast Cancer

VALUE IN HEALTH (2016)

Get Full Text
Add to Collection

Journal

VALUE IN HEALTH
Volume 19, Issue 7, Pages A739-A740

Publisher

Elsevier BV
DOI: 10.1016/j.jval.2016.09.2247

Keywords

-

Categories

Economics

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.